Cost-effectiveness of an in-development adult-formulated 21-valent pneumococcal conjugate vaccine in US adults aged 50 years or older
Shoroq M. Altawalbeh, Angela R. Wateska, Mary Patricia Nowalk, Chyongchiou J. Lin, Lee H. Harrison, William Schaffner, Richard K. Zimmerman, Kenneth J. Smith
Topics & Concepts
MedicinePneumococcal conjugate vaccineVaccinationCohortQuality-adjusted life yearCost effectivenessYoung adultPediatricsCost-effectiveness analysisCohort studyVaccine efficacyPneumococcal infectionsDemographyImmunologyGerontologyStreptococcus pneumoniaeInternal medicineBiologyGeneticsRisk analysis (engineering)BacteriaSociologyPneumonia and Respiratory InfectionsRespiratory viral infections researchGastroesophageal reflux and treatments